Subscribe to GlobalData Explorer to access actionable intelligence spanning 22 industries, 200+ economies and 700k+ companies on a single platform

Number of ongoing Clinical Trials (for drugs) involving Schizophrenia by Phase

  • There are currently 305 ongoing clinical trials involving Schizophrenia

  • Of the 305 trials,81 trials are in Phase II

  • Furthermore, 74 trials are in Phase IV

Number of ongoing Clinical Trials (for drugs) involving Schizophrenia by Phase

Published: October 2021
Source: GlobalData

The global pharmaceutical industry is steadily developing new drugs for Schizophrenia, a Central Nervous System condition. The largest number of ongoing clinical trials for Schizophrenia is conducted in the Asia-Pacific region. North America and Europe are among some of the other prominent regions engaged in Schizophrenia-related drug trials.

Schizophrenia related clinical trial sponsor

Yale University, Sunovion Pharmaceuticals Inc, Centre for Addiction and Mental Health, Shanghai Mental Health Center, Karuna Therapeutics Inc, and University of California Los Angeles are among other notable clinical trial sponsors involved in Schizophrenia. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Schizophrenia  

Paliperidone palmitate (Invega Sustenna, Xeplion, Byannli), Lurasidone hydrochloride (Latuda, SM-13496), and Aripiprazole (Abilify Maintena) are among the key marketed drugs involving Schizophrenia. 

Paliperidone palmitate (Invega Sustenna, Xeplion, Byannli) is an atypical antipsychotic agent belongs to the pyridopyrimidine. It functions via 5-Hydroxytryptamine Receptor 2 (5 HT2 Receptor or HTR2) Antagonist; D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2) Antagonist mechanism of action. It is formulated as extended release (long acting) injectable suspension and powder for suspension for intramuscular route and tablets for suspension for oral route of administration. It is indicated for the treatment of schizophrenia and for the treatment of schizoaffective disorder as monotherapy and as an adjunct to mood stabilizers or antidepressants. Paliperidone palmitate was first approved in 2009 and is marketed globally including the US, the UK, France, Canada, and China by several prominent pharma giants including Johnson & Johnson Pvt Ltd, Janssen-Cilag SpA, J-C Health Care Ltd, and PT. SOHO Industri Pharmasi. 

Lurasidone hydrochloride (Latuda, SM-13496) is an atypical psychotropic agent belonging to the chemical class of benzisothiazole derivatives. It functions via 5-Hydroxytryptamine Receptor 1A (5 HT1A or G 21 or Serotonin Receptor 1A or HTR1A) Agonist; 5-Hydroxytryptamine Receptor 2A (5 HT2A or Serotonin Receptor 2A or HTR2A) Antagonist; 5-Hydroxytryptamine Receptor 7 (5 HT7 or 5 HTX or Serotonin Receptor 7 or HTR7) Antagonist; D2 Dopamine Receptor (Dopamine D2 Receptor or DRD2) Antagonist mechanism of action. It is formulated as film-coated tablets for oral route of administration and also administered through intramuscular route. Latuda is indicated for the treatment of patients with schizophrenia, as monotherapy for the treatment of patients with major depressive episodes associated with bipolar I disorder (bipolar depression), as adjunctive therapy with either lithium or valproate for the treatment of patients with major depressive episodes associated with bipolar I disorder (bipolar depression). It is also indicated for the treatment of schizophrenia in adults aged 18 years and over, for the treatment of schizophrenia in adolescents aged 13 to 17 years, for the treatment of major depressive episode associated with bipolar I disorder (bipolar depression) in pediatric patients (10 to 17 years of age). Lurasidone hydrochloride was first approved in 2010 and is marketed globally including the US, the UK, France, Canada, and China by several prominent pharma giants including Sunovion Pharmaceuticals Inc, Servier Laboratories (Aust) Pty Ltd, Angelini Spa, and Sumitomo Dainippon Pharma Co Ltd



Explore, track and compare industries, economies and companies in a single platform through GlobalData Explorer.​

Single License $700 per month (billed Annually)
Multiple Licenses Connect with a GlobalData representative to discover our offers for multiple licenses​
  • 700K+Companies
  • 22Industries
  • 15K+Reports
  • 200+Countries & Regions
Still looking?

Don’t wait - discover a universe of connected data & insights with your next search. Browse over 28M data points across 22 industries.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company Analytics

Contact the team or request a demo to find out how our data can drive your business forward